PLSE
Pulse Biosciences, Inc.
September 9, 2026 · intraday
- Rarity
- 1.74
- Peak move
- +19.22%
- Float cap
- $861M
Pulse Biosciences is a medical technology company using its patented Nano-pulse Stimulation (NPS) technology to nonthermally clear or kill targeted cells. It has FDA clearance for the Vybrance Percutaneous Electrode System for soft tissue ablation and is developing products for atrial fibrillation and other specialties. Its customers are physicians and healthcare providers performing surgical and cardiac procedures.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
2 events · 0 from SEC or newswire · 0 timed with the moveinsider_salePulse Biosciences COO Liane Teplitsky acquired 1,001 shares of PLSE common stock at an average price of $49.95 per share on September 1, 2026.
analyst_ratingFreedom Capital Markets initiated coverage on Pulse Biosciences with a Buy rating and a $73 price target, citing its nsPFA technology and the atrial fibrillation ablation market opportunity.